Electromed, Inc. (ELMD) P/E Ratio History
ExpensiveTrading at 45.0x vs 5Y avg 34.8x · 85th percentile · Material premium to history · Data 2011–2026
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, Electromed, Inc. (ELMD) trades at a price-to-earnings ratio of 45.0x, with a stock price of $38.68 and trailing twelve-month earnings per share of $1.17.
The current P/E is 29% above its 5-year average of 34.8x. Over the past five years, ELMD's P/E has ranged from a low of 20.0x to a high of 59.1x, placing the current valuation at the 85th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, ELMD trades at a 103% premium to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
The PEG ratio of 3.50 (P/E divided by 48% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, ELMD commands a significant premium over the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ELMD DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ELMD Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ELMD P/E vs Peers
Respiratory and sleep therapy devices peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $7B | 30.5 | - | -22% | |
| $12B | 48.0 | 2.53 | +18% | |
| $154B | 11.6Lowest | 0.39Best | +134% | |
| $102B | 22.0 | - | +31% | |
| $25B | 25.2 | - | +224%Best | |
| $17B | 30.5 | - | -25% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ELMD Historical P/E Data (2011–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q3 | - | $23.41 | $1.17 | 20.0x | -37% |
| FY2026 Q2 | Dec 31 2025 | $29.12 | $1.03 | 28.3x | -10% |
| FY2026 Q1 | - | $24.55 | $0.93 | 26.4x | -16% |
| FY2025 Q4 | Jun 30 2025 | $21.99 | $0.84 | 26.2x | -17% |
| FY2025 Q3 | Mar 31 2025 | $23.86 | $0.79 | 30.2x | -4% |
| FY2025 Q2 | - | $29.55 | $0.75 | 39.4x | +25% |
| FY2025 Q1 | Sep 30 2024 | $21.47 | $0.72 | 29.8x | -6% |
| FY2024 Q4 | Jun 30 2024 | $15.03 | $0.58 | 26.0x | -18% |
| FY2024 Q3 | Mar 31 2024 | $16.15 | $0.50 | 32.5x | +3% |
| FY2024 Q2 | Dec 31 2023 | $10.91 | $0.45 | 24.4x | -23% |
| FY2024 Q1 | Sep 30 2023 | $10.39 | $0.37 | 28.3x | -11% |
| FY2023 Q4 | Jun 30 2023 | $10.71 | $0.36 | 29.8x | -6% |
| FY2023 Q3 | Mar 31 2023 | $10.40 | $0.28 | 36.7x | +16% |
| FY2023 Q2 | Dec 31 2022 | $10.49 | $0.24 | 44.3x | +40% |
| FY2023 Q1 | Sep 30 2022 | $10.25 | $0.23 | 45.2x | +43% |
| FY2022 Q4 | - | $9.64 | $0.27 | 36.0x | +14% |
| FY2022 Q3 | - | $12.44 | $0.26 | 47.2x | +49% |
| FY2022 Q2 | Dec 31 2021 | $13.00 | $0.22 | 59.1x | +87% |
| FY2022 Q1 | - | $10.82 | $0.25 | 43.3x | +37% |
| FY2021 Q4 | Jun 30 2021 | $11.29 | $0.26 | 43.4x | +37% |
| FY2021 Q3 | Mar 31 2021 | $10.54 | $0.37 | 28.5x | -10% |
| FY2021 Q2 | - | $9.81 | $0.41 | 23.9x | -24% |
| FY2021 Q1 | Sep 30 2020 | $10.41 | $0.42 | 24.8x | -22% |
| FY2020 Q4 | - | $15.39 | $0.48 | 32.1x | +2% |
| FY2020 Q3 | - | $11.24 | $0.46 | 24.4x | -23% |
| FY2020 Q2 | - | $8.65 | $0.43 | 20.1x | -36% |
| FY2020 Q1 | Sep 30 2019 | $6.61 | $0.33 | 20.0x | -37% |
| FY2019 Q4 | Jun 30 2019 | $5.45 | $0.23 | 23.7x | -25% |
| FY2019 Q3 | Mar 31 2019 | $5.15 | $0.23 | 22.4x | -29% |
| FY2019 Q2 | Dec 31 2018 | $5.09 | $0.23 | 22.1x | -30% |
| FY2019 Q1 | Sep 30 2018 | $6.50 | $0.24 | 27.1x | -14% |
| FY2018 Q4 | Jun 30 2018 | $5.42 | $0.23 | 23.2x | -27% |
| FY2018 Q3 | Mar 31 2018 | $5.36 | $0.21 | 25.0x | -21% |
| FY2018 Q2 | Dec 31 2017 | $6.07 | $0.25 | 23.9x | -24% |
| FY2018 Q1 | Sep 30 2017 | $7.31 | $0.25 | 28.8x | -9% |
| FY2017 Q4 | Jun 30 2017 | $5.53 | $0.26 | 21.3x | -33% |
| FY2017 Q3 | Mar 31 2017 | $4.93 | $0.19 | 25.9x | -18% |
| FY2017 Q2 | Dec 31 2016 | $3.88 | $0.17 | 22.8x | -28% |
| FY2017 Q1 | Sep 30 2016 | $4.59 | $0.25 | 18.4x | -42% |
| FY2016 Q4 | - | $3.86 | $0.27 | 14.3x | -55% |
| FY2016 Q3 | - | $4.15 | $0.26 | 16.0x | -49% |
| FY2016 Q2 | - | $1.90 | $0.20 | 9.3x | -71% |
| FY2016 Q1 | Sep 30 2015 | $1.80 | $0.12 | 14.4x | -54% |
| FY2015 Q4 | - | $1.85 | $0.13 | 13.7x | -56% |
| FY2015 Q3 | - | $2.51 | $0.14 | 17.9x | -43% |
| FY2015 Q2 | Dec 31 2014 | $2.66 | $0.02 | 168.7x | +434% |
| FY2012 Q4 | Jun 30 2012 | $2.10 | $0.02 | 100.0x | +217% |
| FY2012 Q3 | Mar 31 2012 | $2.90 | $0.06 | 45.8x | +45% |
| FY2012 Q2 | Dec 31 2011 | $3.45 | $0.11 | 30.5x | -4% |
| FY2012 Q1 | Sep 30 2011 | $3.50 | $0.15 | 23.3x | -26% |
| FY2011 Q4 | - | $3.30 | $0.14 | 23.5x | -26% |
| FY2011 Q3 | - | $3.30 | $0.13 | 25.1x | -21% |
| FY2011 Q2 | Dec 13 2010 | $3.40 | $0.15 | 22.4x | -29% |
| FY2011 Q1 | - | $3.71 | $0.14 | 25.8x | -18% |
Average P/E for displayed period: 31.6x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
15+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ELMD — Frequently Asked Questions
Quick answers to the most common questions about buying ELMD stock.
What is ELMD's P/E ratio?
Electromed, Inc. (ELMD) trailing twelve-month P/E ratio is 45.0x, based on TTM diluted EPS of $1.17. The 5-year average P/E is 34.8x and the historical range spans 20.0x to 59.1x.
Is ELMD stock overvalued or undervalued?
ELMD trades at 45.0x P/E, above its 5-year average of 34.8x. The 85th percentile ranking within the 20.0x–59.1x historical range indicates a premium to historical valuation.
Is ELMD stock expensive?
Yes, ELMD is expensive relative to its own history. The current P/E of 45.0x is above the 5-year average of 34.8x and also above the Healthcare sector median of 22.1x. The stock sits at the 85th percentile of its 5-year valuation range.
What is ELMD's historical P/E range?
Over the past 5 years, ELMD's P/E ratio has ranged from 20.0x to 59.1x, with a median of 32.5x and an average of 34.8x. The current P/E of 45.0x places the stock at the 85th percentile of this range. Full historical data spans 2011–2026.
How does ELMD's P/E compare to the S&P 500?
ELMD trades at 45.0x P/E versus the S&P 500 median of 24.4x. The 84% premium to the market typically reflects higher expected earnings growth or quality.
How does ELMD's valuation compare to Healthcare peers?
Electromed, Inc. P/E of 45.0x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ELMD's PEG ratio?
ELMD PEG ratio is 3.50, based on a P/E of 45.0x and EPS growth of 48.3%. A PEG above 2.0 indicates a premium valuation relative to earnings growth — typically considered expensive.
What is ELMD's earnings yield?
ELMD earnings yield is 2.22%, the inverse of its 45.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.